Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amsten
- Development stage
- Unknown
- Lead developer
- Stadmed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Amsten** is an oral fixed-dose antihypertensive and antianginal combination marketed by Stadmed. Each tablet contains amlodipine 5 mg, a dihydropyridine L-type calcium-channel blocker that reduces peripheral vascular resistance through arterial vasodilation, and atenolol 50 mg, a beta-1 adrenergic receptor blocker that lowers heart rate and cardiac workload. It is marketed for hypertension inadequately controlled with either component alone and for angina. ([stadmed-global.com](https://stadmed-global.com/upcp_product/amsten/))
- Brand names
- Amsten
- Other names
- amlodipine + atenololatenolol + amlodipine
02
Targets
ADRB1 (β1)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on Amsten.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amsten.